Press Releases

Aug 04, 2022
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022
- Approximately $9 Million of Product Sales in the Second Quarter, including First Oral TPOXX® Sale to the U.S. Department of Defense and Approximately $5 Million of International Sales – - Received Approximately $60 Million of International Orders for Oral TPOXX® Year to Date, from Ten
Jul 15, 2022
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
SIGA to Supply TPOXX® to Support KaliVir’s Oncolytic Vaccinia Clinical Immunotherapy Program NEW YORK , July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration
Jul 08, 2022
SIGA Technologies Receives Approval from UK for Tecovirimat
Treatment Approved for Smallpox, Monkeypox, Cowpox, and Vaccinia Complications NEW YORK , July 08, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United Kingdom has
Displaying 1 - 10 of 19